Ibodutant was a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group.

As of March 2015[update], it underwent a multicentre double blind efficacy clinical study.

Ibodutant selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations.

A 52-week phase 3 study was terminated as of 2015 because of low response and negative results of study NAK-06.

This drug article relating to the nervous system is a stub.